Craft

Celldex Therapeutics

Stock Price

$39.6

2024-04-05

Market Capitalization

$2.6 B

2024-04-05

Revenue

$6.9 M

FY, 2023

Celldex Therapeutics Summary

Company Summary

Overview
Celldex Therapeutics (formerly known as Avant Immunotherapeutics) is developing targeted therapeutics to address devastating diseases. It offers Immuno-oncology, Therapeutic antibodies, immune system modulators, inflammatory diseases, and other services.
Type
Public
Status
Active
Founded
1983
HQ
Hampton, NJ, US | view all locations
Website
https://celldex.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Anthony S. Marucci

    Anthony S. Marucci, Founder, President, CEO & Director

  • Sarah Boylan Cavanaugh

    Sarah Boylan Cavanaugh, Senior Vice President, Corporate Affairs & Administration

  • Tibor Keler

    Tibor Keler, Founder, Executive Vice President & Chief Scientific Officer

  • Thomas Davis

    Thomas Davis, CMO, SVP Clinical Development

Operating MetricsView all

Patents Issued

300

FY, 2016

LocationsView all

4 locations detected

  • Hampton, NJ HQ

    United States

    53 Frontage Rd #220

  • Fall River, MA

    United States

    151 martine street

  • Needham, MA

    United States

    160 Gould St #202

  • New Haven, CT

    United States

    300 George St #530

Celldex Therapeutics Financials

Summary Financials

Revenue (FY, 2023)
$6.9M
Gross profit (FY, 2023)
$6.6M
Net income (FY, 2023)
($141.4M)
Cash (FY, 2023)
$34.8M
EBIT (FY, 2023)
($154.5M)
Enterprise value
$2.6B

Footer menu